Gene · 5932
RBBP8: RB binding protein 8, endonuclease
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. RBBP8: RB binding protein 8, endonuclease. Genes, record 5932. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/5932
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q99708 | DNA endonuclease RBBP8 | 897 | 4 | Ensembl, GeneID, HGNC |
Source UniProt
Patents60
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4827902 A1 | 2026-10-28 | 10 | Q99708 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 5469 | Q99708 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 5081 | Q99708 | Espacenet |
| EP 4641202 A2 | 2025-10-29 | 4967 | Q99708 | Espacenet |
| JP 2025100656 A | 2025-07-03 | 16 | Q99708 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 5081 | Q99708 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 5469 | Q99708 | Espacenet |
| KR 1020250017231 A | 2025-02-04 | 4967 | Q99708 | Espacenet |
| WO 2025006963 A1 | 2025-01-02 | 37 | Q99708 | Espacenet |
| EP 4464338 A2 | 2024-11-20 | 166 | Q99708 | Espacenet |
1 to 10 of 60
See all 60 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,983
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | RBBP8 papers | Newest fiscal year |
|---|---|---|---|
| P01CA092584 | Structural Cell Biology of DNA Repair Machines | 55 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 33 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 25 | 2025 |
| ZIABC010959 | Relationship between DNA damage detection and signaling | 14 | 2025 |
| ZIABC010283 | DNA repair | 13 | 2025 |
| P30CA006927 | Comprehensive Cancer Center Program at Fox Chase | 12 | 2025 |
| P30CA033572 | Cancer Center Support Grant | 12 | 2025 |
| ZIAAG000741 | Roles Of DNA Helicases In Pathways Required For Maintenance Of Genomic Stability | 12 | 2025 |
| P30CA016086 | Cancer Center Support Grant | 11 | 2025 |
| R01CA198279 | Shaping DNA Damage Response Networks Via Histone H2A Variants | 11 | 2025 |
1 to 10 of 1,983Source NIH's project files
See all 1,983 nih grantsPapers3,043
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The BRCA1-A complex: At the edge of resection and the beauty of restraint. | DNA Repair (Amst) | 2026 | 42826492 | PubTator, text mining | PubMed |
| Structural and thermodynamic analysis of BRCA1 BRCT variants identified in Middle Eastern breast cancer cohorts. | Protein Pept Lett | 2026 | 42692369 | PubTator, text mining | PubMed |
| The tumor suppressor menin is a key scaffold mediator for homologous recombination repair. | Nucleic Acids Res | 2026 | 42578372 | PubTator, text mining | PubMed |
| NEK3 promotes cancer resistance through facilitating CtIP-mediated DNA repair. | DNA Repair (Amst) | 2026 | 42497526 | PubTator, text mining | PubMed |
| Cell-cycle-dependent regulation of DNA end resection by PLK1 and PLK3 without CtIP level modulation. | iScience | 2026 | 42436985 | PubTator, text mining | PubMed |
| Pemphigoid gestationis and anti-SAE2-positive inflammatory myopathy without cutaneous involvement following assisted reproductive technology pregnancy: a rare autoimmune association. | Ital J Dermatol Venerol | 2026 | 42411699 | PubTator, text mining | PubMed |
| Integrating Machine Learning and Structure-Guided Discovery of a Novel Type II SYK Inhibitor for Treating Triple-Negative Breast Cancer. | J Med Chem | 2026 | 42304805 | PubTator, text mining | PubMed |
| SHLD2 loss is a synthetic vulnerability to Polθ inhibition combined with radiotherapy. | Sci Adv | 2026 | 42284420 | PubTator, text mining | PubMed |
| An integrative mutational and network analysis of pancreatic cancer reveals key genes, and signalling pathways. | Funct Integr Genomics | 2026 | 42277390 | PubTator, text mining | PubMed |
| Construction of a novel signature based on CRISPR-Cas9 screening for prognostic prediction in breast cancer. | BMC Cancer | 2026 | 42135732 | PubTator, text mining | PubMed |
1 to 10 of 3,043
See all 3,043 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/5932
GET https://conductscience.org/api/genes/v1/5932/patents?page=2